Department of Oral Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Sci Rep. 2022 Sep 29;12(1):16358. doi: 10.1038/s41598-022-20873-6.
Head and neck squamous cell carcinoma (HNSCC) has become the sixth most common malignant disease worldwide and is associated with high mortality, with an overall 5-year survival rate of less than 50%. Recent studies have demonstrated that aberrantly expressed m6A regulators are involved in multiple biological and pathological processes, including cancers, but the specific mechanisms of m6A regulators in HNSCC are not well elucidated. In this study, we adopted The Cancer Genome Atlas (TCGA)-HNSCC database and performed a consensus clustering analysis to classify the HNSCC samples. Least absolute shrinkage and selection operator (LASSO) regression was applied to construct an m6A signature-based HNSCC risk prediction model. Cell type identification based on estimating relative subsets of RNA transcripts (CIBERSORT) algorithms was adopted to evaluate the immune cell infiltration level in the tumor microenvironment. Based on the expression of m6A regulators in HNSCC, we identified two clusters, cluster 1 (C1) and cluster 2 (C2). C2 showed a better prognosis than C1 and was mainly enriched in the HIPPO, MYC, NOTCH, and NRF signaling pathways. We constructed an m6A signature-based risk score model and classified patients into high- and low-risk score subgroups. The high-risk-score group showed poor clinical characteristics, higher immune infiltration levels, higher chemokine and chemokine receptor expression levels, and lower immune checkpoint gene expression than the low-risk-score subgroup. In conclusion, our comprehensive analysis suggests that the m6A signature-based risk score might function as a good prognostic predictor. Our study may provide novel therapeutic clues and help predict the prognosis of HNSCC.
头颈部鳞状细胞癌(HNSCC)已成为全球第六大常见恶性肿瘤,死亡率高,总体 5 年生存率低于 50%。最近的研究表明,异常表达的 m6A 调节剂参与多种生物学和病理过程,包括癌症,但 m6A 调节剂在 HNSCC 中的具体机制尚不清楚。在本研究中,我们采用了癌症基因组图谱(TCGA)-HNSCC 数据库进行共识聚类分析,对 HNSCC 样本进行分类。最小绝对收缩和选择算子(LASSO)回归用于构建基于 m6A 特征的 HNSCC 风险预测模型。采用基于估计相对 RNA 转录物子集的细胞类型识别(CIBERSORT)算法评估肿瘤微环境中的免疫细胞浸润水平。基于 m6A 调节剂在 HNSCC 中的表达,我们鉴定出两个簇,簇 1(C1)和簇 2(C2)。C2 比 C1 预后更好,主要富集在 HIPPO、MYC、NOTCH 和 NRF 信号通路中。我们构建了基于 m6A 特征的风险评分模型,并将患者分为高风险评分和低风险评分亚组。高风险评分组表现出较差的临床特征、更高的免疫浸润水平、更高的趋化因子和趋化因子受体表达水平以及更低的免疫检查点基因表达水平,低于低风险评分亚组。总之,我们的综合分析表明,基于 m6A 特征的风险评分可能是一个良好的预后预测指标。我们的研究可能为 HNSCC 的治疗提供新的线索,并有助于预测预后。